Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)

Shionogi

Status and phase: Enrolling; Phase 2

Conditions: Pompe Disease

Treatments: Drug: S-606001; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT07123155

2025-522146-40 (EudraCT Number)

2405N1221

Details and patient eligibility

About

The purpose of this study is to evaluate the safety, pharmacodynamics (PD), and exploratory clinical efficacy of S-606001 in adult participants with LOPD as an add-on to ERT.

Enrollment: 45 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

• Participant must be ≥18 years of age and ≥40 kilograms (kg) of body weight at the time of signing the informed consent.

• Participant must have a diagnosis of LOPD based on documentation of 1 of the following:

  1. Deficiency of acid alpha-glucosidase (GAA) enzyme
  2. GAA genotype

• Participant has a %FVC ≥30% and ≤80% in an upright position without mechanical ventilation at screening; or Participant has ≥10% %FVC drop from upright position to supine position and %FVC ≥20% in a supine position.

• Participant performs the 6MWT at screening, as determined by the clinical evaluator, and meets all of the following criteria:

  1. Screening values of 6-minute walk distance (6MWD) are ≥75 meters
  2. Screening values of 6MWD are ≤90% of the predicted value for healthy adults

• Participants must be ERT-experienced, defined as currently receiving ERT and having been receiving ERT for ≥24 months, with no regimen change in the last 6 months.

Key Exclusion Criteria:

• Has a medical condition or any other extenuating circumstance that may pose an undue safety risk to the participant or may compromise his/her ability to comply with or adversely impact protocol requirements.
• Has active infections at screening.
• Malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
• Current or chronic history of liver disease.
• Known biallelic loss of function mutations whether in glycogenin gene (GYG) or in glycogen phosphorylase muscle associated gene(PYGM) .
• Has received any investigational therapy or pharmacological treatment for Pompe disease, within 30 days or 5 half-lives of the therapy or treatment, whichever is longer, before day 1 or is anticipated to do so during the study.
• Has received gene therapy or small interfering ribonucleic acid (RNA) therapy for Pompe disease.
• Participant, if female, is pregnant or breastfeeding at screening.
• Participant, whether male or female, is planning to conceive a child during the study.

Note: Other protocol-specified inclusion and exclusion criteria may apply.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

45 participants in 3 patient groups, including a placebo group

S-606001 Low Dose

Experimental group

Description:

Participants will receive S-606001 at a low dose level twice daily (BID) after a meal for 52 weeks.

Treatment:

Drug: S-606001

S-606001 High Dose

Experimental group

Description:

Participants will receive S-606001 at a high dose level BID after a meal for 52 weeks.

Treatment:

Drug: S-606001

Placebo

Placebo Comparator group

Description:

Participants will receive S-606001 matching placebo BID after a meal for 52 weeks.

Treatment:

Drug: Placebo